Court rules in Endo's favor in compounding case

2 August 2019
endo-big

Ireland-headquartered drugmaker Endo International (Nasdaq: ENDP) has applauded the US District Court for the District of Columbia's ruling supporting the Food and Drug Administration's (FDA) view that vasopressin cannot be used for compounding by outsourcing facilities.

The latest court decision follows an FDA decision in March not to list the antidiuretic hormone on the list of bulk drug substances permitted to be compounded under Section 503B of the Federal Food, Drug and Cosmetic Act.

Endo’s subsidiary Par Sterile Products is the manufacturer of Vasostrict, the only vasopressin product approved by the FDA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics